pharmaphorum

JUNE 8, 2022

The passport means that LentiGlobin will be reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new innovative licensing and access pathway (ILAP) introduced in 2020, which reduces the review time for a new medicine to 150 days.

Gene Silencing 52

Gene Silencing Drugs Medicine Regulation 52

XTalks

SEPTEMBER 12, 2024

Vir Biotechnology’s PSMA-Targeted Therapy Vir Biotechnology — who entered a new licensing agreement with Sanofi this month — secured exclusive rights to a clinical-stage dual-masked PSMA-targeted T-cell engager (SAR446329) for mCRPC patients. Prostate Cancer Awareness Month is a time to act.

Research 52

Research Clinical Trials Clinical Trials Hormones 52

XTalks

NOVEMBER 2, 2020

This includes compromising the functioning of the adrenal glands, which can potentially lead to adrenal insufficiency, resulting in inadequate production of steroid hormones. Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., PONENTE Trial.

Trials 94

Trials FDA Approval Drugs Hormones 94

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MARCH 11, 2021

Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”

Sales 52

Sales Gene Therapy Marketing Gene 52

XTalks

AUGUST 15, 2023

Akeega is a dual-action tablet (DAT) that contains the company’s androgen receptor-targeting hormone therapy Zytiga (abiraterone acetate) and PARP inhibitor (poly [ADP-ribose] polymerase inhibitor) niraparib. Niraparib is also sold by GSK under the name Zejula in other indications. In April 2016, Janssen Biotech, Inc.

FDA Approval 52

FDA Approval Gene Hormones Drugs 52

The Pharma Data

DECEMBER 9, 2020

The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations. announced a research collaboration to develop hormone receptor antagonist (GHRA) peptides as potential treatments for acromegaly, a rare but serious endocrine disorder with significant unmet medical need.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

MARCH 5, 2025

In the pivotal Phase III VERIFY study, researchers evaluated rusfertide, a firstinclass investigational hepcidin mimetic peptide therapeutic designed to mimic the natural hormone that regulates iron, to see if it could reduce the need for regular blood removals (phlebotomies).

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

NOVEMBER 26, 2024

on these sales under an exclusive licensing agreement that allows Janssen to develop, produce and market daratumumab. Xtandi is also prescribed for metastatic prostate cancer that continues to respond to hormone therapy. Genmab earns royalties from Janssen Biotech, Inc. List price of Xtandi: $14,322.47 per month.

Sales 105

Sales FDA Approval Drugs Marketing 105